Background Sickle cell disease is an inherited disorder characterized by the presence of
sickle hemoglobin (HbS). The process of Hb molecule polymerization is a pivotal step in the …

Objective Voxelotor, a FDA-approved drug for the treatment of patients with sickle cell
disease (SCD), inhibits hemoglobin S (HbS) polymerization and increases total hemoglobin …

Objectives Voxelotor was recently approved for use in the United States as a treatment for
sickle cell disease (SCD) and has been shown to interfere with the quantitation of …

Background: Voxelotor (GBT440) is a small molecule allosteric effector with high specificity
for hemoglobin (Hb) that inhibits Hb S polymerization by increasing hemoglobin oxygen …

Voxelotor, a sickle hemoglobin polymerization inhibitor, was approved by the US Food and
Drug Administration to treat sickle cell disease (SCD) in November 2019. This article …

Abstract Background Deoxygenated sickle hemoglobin (HbS) polymerization drives the
pathophysiology of sickle cell disease. Therefore, direct inhibition of HbS polymerization has …

Voxelotor is a novel agent in the management of sickle cell disease. It is an inhibitor of Hb S
(HBB: c. 20A> T) polymerization that reversibly binds to hemoglobin (Hb), stabilizing it in the …

Background: Sickle cell disease (SCD) is a lifelong, inherited blood disorder, resulting from
a mutation in the hemoglobin (Hb) subunit β gene, that leads to sickle hemoglobin (HbS) …

Background Sickle cell disease (SCD) is a devastating, multisystemic disorder that affects
millions of people worldwide. The earliest clinical manifestations of SCD can affect infants as …

Voxelotor (Oxbryta™) is a haemoglobin S polymerization inhibitor that has been developed
for the treatment of sickle cell disease. In November 2019, voxelotor received its first global …